26.08.2013 Views

GM crops: Reaping the benefits, but not in Europe - Europabio

GM crops: Reaping the benefits, but not in Europe - Europabio

GM crops: Reaping the benefits, but not in Europe - Europabio

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Patents and Royalties<br />

Biotech companies <strong>in</strong>vest very large sums <strong>in</strong> <strong>the</strong> development of <strong>the</strong> most useful new varieties.<br />

Just as with o<strong>the</strong>r technologies, this research is economically viable because <strong>the</strong> <strong>in</strong>ventions can be<br />

patented. Farmers have <strong>the</strong> choice between high performance <strong>GM</strong> seeds that can be more expensive<br />

than conventional seeds because royalties are built <strong>in</strong>to <strong>the</strong> price, or cheaper conventional seeds.<br />

Their choice will depend on <strong>the</strong>ir expected <strong>in</strong>dividual <strong>benefits</strong>.<br />

Royalties as a cost component of transgenic <strong>crops</strong><br />

Cost comparison - Conventional & Biotech Soy (Brasil)<br />

This graph shows why farmers <strong>in</strong> Brazil tend to choose biotech soy. Despite higher seed prices due to<br />

royalties, <strong>the</strong>y eventually save $ 48.80 per hectare, ma<strong>in</strong>ly due to reduced herbicide <strong>in</strong>put.<br />

US$ per hectare<br />

350<br />

300<br />

250<br />

200<br />

150<br />

100<br />

50<br />

0<br />

Market concentration?<br />

US$ 48,80<br />

ROYALTY<br />

Conventional Transgenic<br />

SEEDS HERBICIDES<br />

MACHINE<br />

OPERATION<br />

OTHERS<br />

Source<br />

Conab/Abrasem/Celeres/<br />

ISAAA/Kleffmann<br />

Many <strong>GM</strong> seeds are be<strong>in</strong>g developed by mult<strong>in</strong>ational companies, though <strong>the</strong>re is extensive ongo<strong>in</strong>g<br />

research by SMEs and public universities. High R&D and regulatory costs and lead times constitute<br />

immense market entry barriers for smaller companies. A new advisory report to <strong>the</strong> Dutch government<br />

states that <strong>the</strong>re are no <strong>in</strong>dications whatsoever that market concentration is somehow <strong>in</strong>herent to <strong>GM</strong><br />

technology 15 .<br />

In India, <strong>the</strong> <strong>in</strong>troduction and widespread adoption of two Bt-cotton traits developed by mult<strong>in</strong>ational<br />

companies has opened <strong>the</strong> way to four Bt-cotton traits developed by Indian or Ch<strong>in</strong>ese companies. 16<br />

7

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!